Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience
Authors
Keywords
-
Journal
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Volume 27, Issue 12, Pages 1471-1480
Publisher
Wiley
Online
2013-04-24
DOI
10.1111/jdv.12172
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chronic Myelogenous Leukemia
- (2017) Susan O'Brien et al. Journal of the National Comprehensive Cancer Network
- Hair Depigmentation and Vitiligo-like Lesions in a Leukaemic Paediatric Patient during Chemotherapy with Dasatinib
- (2012) V Brazzelli et al. ACTA DERMATO-VENEREOLOGICA
- Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™)
- (2012) Ah Young Cho et al. Annals of Dermatology
- Topical Psoralen Plus UV-A Therapy for Tyrosine Kinase Inhibitor–Induced Hand-Foot Syndrome
- (2012) ARCHIVES OF DERMATOLOGY
- Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations
- (2012) Bella Pajares et al. Clinical & Translational Oncology
- Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization
- (2012) Aaron M. Drucker et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
- (2012) R A Larson et al. LEUKEMIA
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
- (2011) H. M. Kantarjian et al. BLOOD
- Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib
- (2011) IRIS AMITAY-LAISH et al. Dermatologic Therapy
- Dasatinib
- (2011) Paul L. McCormack et al. DRUGS
- Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
- (2011) Hagop M Kantarjian et al. LANCET ONCOLOGY
- Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate
- (2011) Valeria Brazzelli et al. PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE
- Lichenoid Drug Eruption with Palmoplantar Hyperkeratosis due to Imatinib Mesylate: A Case Report and a Review of the Literature
- (2010) N Kuraishi et al. ACTA DERMATO-VENEREOLOGICA
- Panniculite neutrophilique récidivante chez une patiente traitée par imatinib mésilate puis dasatinib pour une leucémie myéloïde chronique
- (2010) A. de Masson et al. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE
- Practical management of tyrosine kinase inhibitor-associated side effects in GIST
- (2010) Heikki Joensuu et al. CANCER TREATMENT REVIEWS
- Imatinib mesylate–induced pseudoporphyria
- (2010) Adar T. Berghoff et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study
- (2010) Francis J Giles et al. Expert Review of Hematology
- Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily
- (2009) Hagop Kantarjian et al. CANCER
- Stevens-Johnson Syndrome Induced by Combination of Imatinib and Allopurinol
- (2009) Huei-Jen Hsieh et al. CHEMOTHERAPY
- Imatinib: a designer drug, another cutaneous complication
- (2009) E. Dickens et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- (2009) Jorg Hartmann et al. CURRENT DRUG METABOLISM
- The toxicities of modern targeted therapies—learning from the price of progress
- (2009) Francis J. Giles Targeted Oncology
- Imatinib-Induced Hand-Foot Syndrome in a Patient With Metastatic Gastrointestinal Stromal Tumor
- (2008) Maxime Battistella et al. ARCHIVES OF DERMATOLOGY
- Bullous Sweet Syndrome in a Patient With t(9;22)(q34;q11)-Positive Chronic Myeloid Leukemia Treated With the Tyrosine Kinase Inhibitor Nilotinib
- (2008) Kjell Matthias Kaune et al. ARCHIVES OF DERMATOLOGY
- Nilotinib
- (2008) M. W. Deininger CLINICAL CANCER RESEARCH
- Drug-induced phototoxicity evoked by inhibition of human ABC transporter ABCG2: development ofin vitrohigh-speed screening systems
- (2008) Ai Tamura et al. Expert Opinion on Drug Metabolism & Toxicology
- Skin and oral lesions associated to imatinib mesylate therapy
- (2008) Fernanda Gonçalves Basso et al. SUPPORTIVE CARE IN CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now